Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer
Manage episode 280035857 series 103551
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon’s role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.